RARE DISEASERESEARCH ATLAS

ORPHA:93329

Autosomal recessive omodysplasia

high confidenceSubtype of disorder

Also known as: Micromelic dysplasia-dislocation of radius syndrome

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

30

32.9th percentile

Trials

0

Interventional, condition-specific

Researchers

183

Distinct authors in sample

Gene link

GPC6

Strong

Readiness

2/6

Stages with a signal

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

autosomal recessive omodysplasia · micromelic dysplasia-dislocation of radius syndrome · omodysplasia type 1 · omodysplasia, autosomal recessive

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — GPC6

  2. LiteraturePresent

    30 matched papers (15 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (GPC6).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

30

30 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

30 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

15 in the last 10 years · high confidence · 32.9th percentile (publications denominator)

Phrase hits: 30 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

183

Distinct author names in 30 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Bonafé L2 papers · 2009
    Papers in Europe PMC
  2. 02
    Chugh SS2 papers · 2010

    The Heart Institute, 5702 South Tower, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA. sumeet.chugh@cshs.org

    Papers in Europe PMC
  3. 03
    Crespo A2 papers · 2018

    Department of Biotechnology, Neiker-Tecnalia Arkaute, 01080, Vitoria-Gasteiz, Spain. ainaracsu@gmail.com.

    Papers in Europe PMC
  4. 04
    Fernández-Vega I2 papers · 2018

    Servicio de Patología. Hospital Universitario de Araba, Álava, 01009, Spain. ivan_fernandez_vega@hotmail.com.

    Papers in Europe PMC
  5. 05
    Filmus J2 papers · 2022

    Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada jorge.filmus@sri.utoronto.ca.

    Papers in Europe PMC
  6. 06
    García B2 papers · 2018

    University Institute of Oncology of Asturias, Oviedo, Spain. garciabeatriz@uniovi.es.

    Papers in Europe PMC
  7. 07
    García-Suárez O2 papers · 2018

    Department of Morphology and Cell Biology, University of Oviedo, 33006, Oviedo, Spain. garciaolivia@uniovi.es.

    Papers in Europe PMC
  8. 08
    Gustavson KH2 papers · 2009
    Papers in Europe PMC
  9. 09
    Liu C2 papers · 2026

    Emergency Department, The Second Hospital of Tangshan, Tangshan, 063000, People's Republic of China.

    Papers in Europe PMC
  10. 10
    Mortier G2 papers · 2020

    Center of Medical Genetics, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

Broader category omodysplasia also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Broader category: omodysplasia

0

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Parent-category matching found a broader label but no interventional trials under it. How we count trials.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Autosomal recessive omodysplasia" OR "Micromelic dysplasia-dislocation of radius syndrome" OR "Micromelic dysplasia-dislocation of the radius syndrome" OR "omodysplasia type 1" OR "omodysplasia, autosomal recessive"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Autosomal recessive omodysplasia" OR "Micromelic dysplasia-dislocation of radius syndrome" OR "Micromelic dysplasia-dislocation of the radius syndrome" OR "omodysplasia type 1" OR "omodysplasia, autosomal recessive" OR "GPC6" OR "autosomal genetic disease"

Recall-expansion terms: GPC6, autosomal genetic disease

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"omodysplasia"

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T04:16:14.881Z